Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.89 |
| ▸ | PER2 | O15055 | 2/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282897 | 0.94 | PIK3CD (1.00) | PIK3CDPER2CRY2GRM2POLB | |
| SCHEMBL12413745 | 0.86 | PIK3CD (0.79) | PIK3CDPER2CRY2POLBAR | |
| SCHEMBL12252012 | 0.79 | PIK3CD (0.72) | PIK3CDPER2CRY2GRM2GRIN1 | |
| SCHEMBL21649532 | 0.76 | PIK3CD (0.53) | PIK3CDPER2CRY2GRM2GRIN1 | |
| SCHEMBL13791864 | 0.73 | PIK3CD (0.62) | PIK3CDPER2CRY2GRM2GRIN1 | |
| SCHEMBL8157591 | 0.73 | PIK3CD (0.50) | PIK3CDPER2CRY2GRM2KDM4E | |
| SCHEMBL8240286 | 0.73 | PIK3CD (0.63) | PIK3CDPER2CRY2GRM2GRIN1 | |
| SCHEMBL6360878 | 0.72 | — | — | |
| SCHEMBL3177915 | 0.72 | PIK3CD (0.58) | PIK3CDPER2CRY2GRM2KDM4E | |
| SCHEMBL8272699 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | PIK3CD 815/4885PER2 3670/4885CRY2 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.